Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct:143:110142.
doi: 10.1016/j.mehy.2020.110142. Epub 2020 Jul 26.

High dose folic acid is a potential treatment for pulmonary hypertension, including when associated with COVID-19 pneumonia

Esko Wiltshire  1 , Alexia Sophie Peña  2 , Karen MacKenzie  3 , Geoffrey Shaw  4 , Jennifer Couper  2
Affiliations

High dose folic acid is a potential treatment for pulmonary hypertension, including when associated with COVID-19 pneumonia

Esko Wiltshire et al. Med Hypotheses. 2020 Oct.

Abstract

Background: Pulmonary hypertension is a significant complication for some patients with COVID-19 pneumonia, especially those requiring intensive care. Tachyphylaxis to the current therapy, inhaled nitric oxide (iNO), is also common. In vitro, folic acid directly increases nitric oxide (NO) production and extends its duration of action; effects which could be of benefit in reversing pulmonary hypertension and severe hypoxaemia. Our work has shown that, in the systemic circulation, folic acid in high dose rapidly improves nitric oxide mediated vasodilation, by activating endothelial nitric oxide synthase (eNOS).

Hypothesis: A similar effect of high dose folic acid on pulmonary endothelial function would be expected from the same mechanism and would lead to improvement in pulmonary perfusion. We therefore hypothesise that folic acid, 5 mg or greater, is a useful therapeutic option for pulmonary hypertension and/or refractory severe hypoxaemia, in patients with severe COVID-19 associated pneumonia in whom NO therapy is considered, with a very low risk of adverse effects.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Comment in

References

    1. Dunlap B., Weyer G. Am Fam Phys. 2016;94:464–469. - PubMed
    1. Rosenzweig E.B., Abman S.H., Adatia I., Beghetti M., Bonnet D., Haworth S. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J. 2019;53(1):1801916. - PMC - PubMed
    1. Chen L., Liu P., Gao H., Sun B., Chao D., Wang F. Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in beijing. Clin Infect Dis. 2004;39(10):1531–1535. - PMC - PubMed
    1. Itelman E., Wasserstrum Y., Segev A., Avaky C., Negru L., Cohen D. Clinical characterization of 162 COVID-19 patients in Israel: preliminary report from a large tertiary center. Israel Med Assoc J. 2020;22:271–274. - PubMed
    1. Stroes E.S., van Faassen E.E., Yo M., Martasek P., Boer P., Govers R. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res. 2000;86:1129–1134. - PubMed

MeSH terms

LinkOut - more resources